Adherence to oral antineoplastic therapy can shape outcomes in advanced NSCLC, but real-world data is often limited. The prospective LOADH study addresses this gap in Spain, and APICES was acknowledged for supporting key study activities.
ICH E6(R3) updates how GCP is applied in modern trials, with clearer expectations on risk-based quality management, data governance, and roles. This article summarizes the practical changes and how APICES is preparing teams and processes to work under the updated framework.
ASCO 2025 brought the oncology community together in Chicago to focus on how clinical trials translate science into practice. APICES attended, met with peers, and left with clear themes around immunotherapy, targeted treatments, and precision medicine.
APICES was acknowledged during a presentation at ESMO Gynaecological Cancers Congress 2025 for its ongoing CRO support in the international phase III BEATcc trial, evaluating atezolizumab with bevacizumab plus chemotherapy in advanced cervical cancer.
What does EGFR mutation prevalence look like in early-stage resectable NSCLC in Spain when you base it on routine surgical cases? The ORIGEN study explores this question, and APICES was acknowledged for supporting multiple study activities.
In 2025, APICES achieved Silver EcoVadis recognition and aligned with SBTi, reinforcing its approach to sustainability and responsible business practices in clinical research. This article explains what those recognitions mean and how they connect to day-to-day work.
A pooled real-world dataset, 427 cancer patients, and one side effect that can derail pain care. The NALOPOOL analysis puts naloxegol under the spotlight, and APICES contributed as an author and in the statistics.
APICES is putting sustainability under the microscope, not just in words but in verified action. See what the 2024 EcoVadis and CDP recognitions say about how APICES runs clinical research.
What do real-world bladder cancer outcomes in Spain look like when you zoom in on routine care? The BLARWE multicenter study tackles that, and APICES was acknowledged for supporting key study activities behind the scenes.
APICES has been acknowledged for its contribution to PARASEC, a retrospective analysis of treatment patterns in Spanish prostate cancer patients treated with darolutamide in the ARAMIS trial, presented at ASCO GU 2025.
APICES has been acknowledged in The Journal of Obstetrics and Gynaecology for its medical writing contribution to a retrospective study on fertility preservation counselling and practice among women with Hodgkin and non-Hodgkin lymphoma.
